Emily Boevers, Bradley D McDowell, Sarah L Mott, Anna M Button, Charles F Lynch
{"title":"Insurance Status Is Related to Receipt of Therapy and Survival in Patients with Early-Stage Pancreatic Exocrine Carcinoma.","authors":"Emily Boevers, Bradley D McDowell, Sarah L Mott, Anna M Button, Charles F Lynch","doi":"10.1155/2017/4354592","DOIUrl":null,"url":null,"abstract":"<p><p><i>Objectives</i>. The study objective was to determine how insurance status relates to treatment receipt and overall survival for patients with early-stage pancreatic exocrine carcinoma. <i>Methods</i>. SEER data were evaluated for 17,234 patients diagnosed with Stage I/II pancreatic exocrine carcinoma. Multivariate regression models controlled for personal characteristics to determine whether insurance status was independently associated with overall survival and receipt of radiation/surgery. <i>Results</i>. Odds of receiving radiation were 1.50 and 1.75 times higher for insured patients compared to Medicaid and uninsured patients, respectively (<i>p</i> < 0.01). Insured patients had 1.68 and 1.57 times increased odds of receiving surgery compared to Medicaid and uninsured patients (<i>p</i> < 0.01). Risk of death was 1.33 times greater (<i>p</i> < 0.01) in Medicaid patients compared to insured patients; when further adjusted for treatment, the risk of death was attenuated but remained significant (HR = 1.16, <i>p</i> < 0.01). Risk of death was 1.16 times higher for uninsured patients compared to insured patients (<i>p</i> = 0.02); when further adjusted for treatment, the risk of death was no longer significant (HR = 1.01, <i>p</i> = 0.83). <i>Conclusions</i>. Uninsured and Medicaid-insured patients experience lower treatment rates compared to patients who have other insurances. The increased likelihood of treatment appears to explain the insured group's survival advantage.</p>","PeriodicalId":15366,"journal":{"name":"Journal of Cancer Epidemiology","volume":"2017 ","pages":"4354592"},"PeriodicalIF":1.8000,"publicationDate":"2017-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2017/4354592","citationCount":"12","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Cancer Epidemiology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1155/2017/4354592","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2017/4/10 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 12
Abstract
Objectives. The study objective was to determine how insurance status relates to treatment receipt and overall survival for patients with early-stage pancreatic exocrine carcinoma. Methods. SEER data were evaluated for 17,234 patients diagnosed with Stage I/II pancreatic exocrine carcinoma. Multivariate regression models controlled for personal characteristics to determine whether insurance status was independently associated with overall survival and receipt of radiation/surgery. Results. Odds of receiving radiation were 1.50 and 1.75 times higher for insured patients compared to Medicaid and uninsured patients, respectively (p < 0.01). Insured patients had 1.68 and 1.57 times increased odds of receiving surgery compared to Medicaid and uninsured patients (p < 0.01). Risk of death was 1.33 times greater (p < 0.01) in Medicaid patients compared to insured patients; when further adjusted for treatment, the risk of death was attenuated but remained significant (HR = 1.16, p < 0.01). Risk of death was 1.16 times higher for uninsured patients compared to insured patients (p = 0.02); when further adjusted for treatment, the risk of death was no longer significant (HR = 1.01, p = 0.83). Conclusions. Uninsured and Medicaid-insured patients experience lower treatment rates compared to patients who have other insurances. The increased likelihood of treatment appears to explain the insured group's survival advantage.
期刊介绍:
Journal of Cancer Epidemiology is a peer-reviewed, open access journal that publishes original research articles, review articles, case reports, and clinical studies in all areas of cancer epidemiology.